Your session is about to expire
← Back to Search
Giredestrant for Endometrial Cancer (EndomERA Trial)
EndomERA Trial Summary
This trial looks at how safe and effective a new cancer treatment is for endometrial cancer.
EndomERA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 221 Patients • NCT04436744EndomERA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken strong CYP3A4 drugs recently.My blood and organs are functioning well.I don't have any health issues that would make it unsafe for me to try a new drug.My cancer has spread beyond its original location.I have not received cancer treatment in the last 28 days.I am willing and able to follow all study procedures, including biopsies.I have not received any treatment for endometrial cancer.I have heart problems or have had them in the past.I haven't had major surgery in the last 28 days and don't expect to need one during the study.I have not needed IV antibiotics for serious infections in the last 7 days.I can and will take pills.I am willing and able to follow the study's schedule and procedures.My liver disease is moderate to severe.I am fully active or can carry out light work.I do not have any serious health issues that would make it unsafe for me to join the study.My MRI shows my cancer has not deeply invaded the muscle layer of my uterus.I have tested negative for HIV or am stable on HIV treatment.I have a condition that affects my body's ability to absorb nutrients or causes blockage in my intestines.I have a serious heart condition.I am scheduled for surgery during or within 10 days after the study treatment.My cancer is not the common type but one of the rarer forms like serous or clear cell.I have active tuberculosis.I am willing to undergo at least 6 treatment cycles before considering surgery.I have Grade 1 endometrial cancer and am willing to undergo 6 treatment cycles.I haven't had any other cancers in the last 5 years, or if I did, they were not likely to spread or be fatal.
- Group 1: Giredestrant
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What can be said about the potential risks of Giredestrant treatment?
"Based on the available research, our team at Power gave Giredestrant a score of 2 out of 3. This is because it has been evaluated in Phase 2 trials and only data regarding safety have emerged thus far."
Is there currently an effort to enroll participants in this investigation?
"According to clinicaltrials.gov, this research is currently in the recruitment phase. The trial was published on March 14th of 2023 and has had its most recent update recorded as February 22nd of the same year."
How many participants are recruited for this clinical research?
"Indeed, the information available on clinicaltrials.gov attests that this trial is still recruiting participants. It was initially listed on March 14th 2023 and has since been revised as of February 22nd 2023. 45 volunteers are needed at a single site for enrollment in this study."
Share this study with friends
Copy Link
Messenger